Literature DB >> 6768573

Pharmacokinetics of sodium valproate in epileptic patients: prediction of maintenance dosage by single-dose study.

G J Schapel, R G Beran, C J Doecke, W J O'Reilly, P A Reece, R H Rischbieth, L N Sansom, P E Stanley.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6768573     DOI： 10.1007/bf00561679

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  17 in total

1.  Letter: Sodium valproate and platelet function.

Authors:  H von Voss; C Petrich; D Karch; H U Schulz; U Göbel
Journal:  Br Med J       Date:  1976-07-17

2.  Sodium valproate: a new anticonvulsant.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1977-11-18       Impact factor: 1.909

3.  Principles for clinical testing of antiepileptic drugs.

Authors: 
Journal:  Epilepsia       Date:  1973-12       Impact factor: 5.864

4.  Controlled trial of sodium valproate in severe epilepsy.

Authors:  A Richens; S Ahmad
Journal:  Br Med J       Date:  1975-11-01

5.  Blood levels of drug at the equilibrium state after multiple dosing.

Authors:  J G Wagner; J I Northam; C D Alway; O S Carpenter
Journal:  Nature       Date:  1965-09-18       Impact factor: 49.962

6.  Early experience with sodium valproate.

Authors:  M Ronthal; P S Terespolsky
Journal:  S Afr Med J       Date:  1976-11-20

7.  Disposition of sodium valproate in epileptic patients.

Authors:  E Perucca; G Gatti; G M Frigo; A Crema; S Calzetti; D Visintini
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

8.  Steady-state kinetics of valproic acid in epileptic patients.

Authors:  J Bruni; B J Wilder; L J Willmore; R J Perchalski; H J Villarreal
Journal:  Clin Pharmacol Ther       Date:  1978-09       Impact factor: 6.875

9.  Pharmacokinetics of di-n-propylacetate in epileptic patients.

Authors:  F Schobben; E van der Kleijn; F J Gabreëls
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

10.  Disposition of valproic acid in man.

Authors:  R Gugler; A Schell; M Eichelbaum; W Fröscher; H U Schulz
Journal:  Eur J Clin Pharmacol       Date:  1977-10-14       Impact factor: 2.953
View more
  5 in total

1.  A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy.

Authors:  Christelle Rodrigues; Stéphanie Chhun; Catherine Chiron; Olivier Dulac; Elisabeth Rey; Gérard Pons; Vincent Jullien
Journal:  Eur J Clin Pharmacol       Date:  2018-03-21       Impact factor: 2.953

Review 2.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

3.  First-dose and steady-state pharmacokinetics of valproic acid in children with seizures.

Authors:  K Hall; N Otten; J Irvine-Meek; M Leroux; D Budnick; M Verma; S S Seshia
Journal:  Clin Pharmacokinet       Date:  1983 Sep-Oct       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

5.  The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child.

Authors:  J M Orr; K Farrell; F S Abbott; S Ferguson; W J Godolphin
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.